Screen-detected cognitive impairment, psychological distress, and quality of life in cancer patients undergoing chemotherapy in Yemen Authors: Al-Hassan Alkhafaji, Haidara Alkhafaji, Mohammed Alabsi, Mohammed Alarasi, Sayida Al-Jamei Published: 2026 ABSTRACT BackgroundCancer care in Yemen faces limited data and resources. Chemotherapy may cause cognitive, psychological, and quality-of-life complications. This study assesses the prevalence of screen-positive cognitive impairment (based on MoCA screening), anxiety, depression, and quality-of-life outcomes, as well as their associated factors, among Yemeni patients.MethodsA cross-sectional study was conducted in June–July 2025 at the National Oncology Center, Sana’a, involving adult cancer patients receiving chemotherapy. Cognitive function (MoCA), anxiety/depression (HADS), and quality of life (SF-12) were assessed via structured interviews, and data were analyzed using descriptive statistics and multiple regression (SPSS v28, p < 0.05).ResultsAmong 167 patients, most were male (64.7%), married (83.8%), and in advanced cancer stages (81.3%). Only 6% had normal cognition, while 94% demonstrated screen-positive cognitive impairment, particularly in language and visuospatial domains. Borderline or abnormal anxiety and depression were observed in approximately 20% of patients. Mean PCS-12 (40.4) and MCS-12 (43.2) scores indicated reduced health-related quality of life. In multivariable regression, the cognitive model was significant and explained 41.7% of the variance (adjusted R² = 0.417). Older age (B = − 2.39), male sex (B = − 3.43), and smoking (B = − 1.42) were associated with lower cognition, whereas higher education was positively associated (B = 2.34). The PCS-12 and MCS-12 models explained 11.6% (adjusted R² = 0.046) and 10.0% (adjusted R² = 0.028) of the variance but were not significant overall. Higher education (B = 1.49) and smoking (B = − 2.44) were associated with physical health, while employment (B = 3.71) and metastasis (B = 3.41) were associated with mental health.ConclusionCognitive, psychological, and quality-of-life impairments are highly prevalent among Yemeni cancer patients receiving chemotherapy. Education, lifestyle, and clinical factors significantly influence these outcomes, underscoring the need for tailored interventions and supportive care in resource-limited settings. These findings can guide policy and clinical practice by promoting routine screening and tailored supportive care in oncology settings. Introduction Cancer remains a major global health challenge, with approximately 20 million new cases and 9.7 million deaths reported in 2022, according to GLOBOCAN estimates [1]. Projections indicate a rise to around 35 million new cases by 2050—a roughly 76–77% increase—and 18.5 million deaths—an increase of nearly 90% [2]. This anticipated surge underscores the urgent need for effective global strategies targeting prevention, early detection, and equitable access to cancer control measures [1]. In Yemen, cancer represents a significant public health concern, though detailed epidemiological data remain limited. Analysis of GLOBOCAN 2020 indicates a crude incidence rate (CIR) of 55.2 per 100,000, with an age-standardized rate (ASR) of 97.0 per 100,000 and a cumulative risk (ages 0–74) of 22.0 per 100,000 [3]. The ongoing conflict has further compounded the burden of cancer, with nearly half of healthcare facilities partially or completely inoperable, critical shortages of medical supplies, and limited access to specialized treatments, including oncology services. Only 149 of 5,042 facilities remain fully functional, forcing patients to travel long distances through hazardous areas to reach care [4]. Cancer treatment often involves multimodal approaches—combining chemotherapy, radiation therapy, immunotherapy, and surgery—with increasing emphasis on precision-based regimens. Chemotherapy, a longstanding cornerstone of cancer therapy, employs cytotoxic agents to eliminate rapidly dividing cells [5, 6]. While effective, its lack of tumor selectivity frequently leads to adverse effects on healthy tissues, causing symptoms such as nausea, vomiting, fatigue, peripheral neuropathy, alopecia, pain, and importantly, cognitive impairment [7–10]. Cognitive dysfunction, commonly experienced by cancer patients undergoing chemotherapy, manifests as difficulties with memory, attention, and executive function. Cancer-related cognitive impairment (CRCI) refers to a decline in cognitive function associated with cancer and/or its treatment, including chemotherapy, and may involve deficits in memory, attention, processing speed, and executive functioning. CRCI has been shown to affect every day functioning and quality of life in patients and survivors of cancer [11]. This “chemo brain” can significantly diminish quality of life and daily functioning, with symptoms persisting for months or even years after treatment completion in a substantial subset of patients [8, 9, 12]. Alongside these cognitive challenges, chemotherapy exerts a substantial psychological toll. Patients frequently experience mood disturbances, anxiety, and depression, driven not only by the physiological impacts of treatment but also by emotional stressors such as uncertainty about prognosis, loss of normal functioning, and changes in body image [13–15]. This interplay between cognitive and psychological symptoms underscores the complex burden chemotherapy imposes on patients. This burden may be further intensified in settings like Yemen, where ongoing humanitarian crises have disrupted healthcare infrastructure and limited access to supportive care. Factors such as malnutrition, anemia, and comorbidities, coupled with sociocultural barriers like low health literacy and stigma around mental health, could exacerbate the risk and severity of chemotherapy-induced cognitive and psychological dysfunction [16]. To better understand the relationship between chemotherapy and cognitive outcomes in Yemeni patients, this study utilized a culturally adapted version of the Montreal Cognitive Assessment (MoCA) [17], alongside the Hospital Anxiety and Depression Scale (HADS) and the 12-item Short Form Health Survey (SF-12). Together, these assessments aim to investigate the prevalence of screen-detected cognitive impairment, anxiety, depression, and quality of life, providing crucial insights that could inform tailored interventions and improve cancer care outcomes in this challenging context. Importantly, MoCA results in this study are interpreted as screen-positive indicators of cognitive vulnerability rather than diagnostic confirmation of cognitive impairment, particularly given the influence of educational attainment and literacy on test performance. To date, there has been no published investigation addressing these outcomes within the Yemeni population; therefore, this study represents the first effort to evaluate these concerns in this setting and to generate evidence that could guide clinical practice and policy planning in the region. To situate this study within a conceptual framework, we drew on the Biopsychosocial Model, which emphasizes that health outcomes result from the interaction of biological, psychological, and social factors. In the context of chemotherapy-induced cognitive impairment and psychological distress, biological factors include cancer stage, chemotherapy exposure, and comorbidities; psychological factors include anxiety, depression, and coping strategies; and social factors include education, employment, and family support. This framework guided our selection of variables and informed the interpretation of findings, allowing for a holistic understanding of the factors associated with cognitive function and health-related quality of life in Yemeni cancer patients. Accordingly, the objective of this study is to determine the prevalence and factors associated with chemotherapy-related screen-detected cognitive impairment, anxiety, depression, and quality of life among Yemeni cancer patients using validated Arabic versions of the MoCA, HADS, and SF-12 instruments. Methods Study design, setting, and participants A cross-sectional study was conducted between June and July 2025 at the National Oncology Center in Sana’a, Yemen, a primary referral facility for cancer care. The study population consisted of adult cancer patients (aged 18 years and above) who had been diagnosed with any active type of cancer and were receiving chemotherapy in either the inpatient or outpatient treatment units. Exclusion criteria included patients with brain cancer or brain metastases, those not receiving chemotherapy, patients with a history of psychiatric or neurological disorders, patients taking medications that could affect cognitive function, and individuals who declined to provide informed consent. Eligible patients were approached using a convenience sampling method during their treatment visits. Nearly all approached patients consented to participate. Those who agreed were informed about the study objectives and provided written informed consent. Data were collected through structured surveys administered via face-to-face interviews by trained clinical pharmacists, with each session lasting approximately 20–30 min. This approach ensured that no language barriers were encountered and that participants clearly understood all items. Hospital records were reviewed to verify eligibility and supplement patient-reported information. Sample size calculation The study aimed to recruit oncology patients for multiple regression analysis with fourteen independent variables. Recruitment was constrained by limited patient access and ethical considerations regarding participant burden. According to Green (1991), the minimum sample size for regression analysis is 50 plus 8 participants per independent variable for testing the overall model, which corresponds to 162 participants for fourteen independent variables. For testing individual independent variables, Green (1991) recommends a sample size of 104 plus the number of independent variables, requiring 118 participants in our case. Our final sample of 167 participants exceeds both thresholds, ensuring sufficient power for the planned analyses [18]. Study instrument The instrument used for data collection in this study was composed of several parts, designed to comprehensively assess the participants’ sociodemographic background, clinical profile, cognitive function, psychological state, and quality of life. Sociodemographic and clinical data were collected through a combination of direct interviews and medical record reviews. Participants were asked questions about their age, gender, occupation, marital status, level of education, smoking habits, and qat chewing status. Clinical information was retrieved from patients’ medical files at the National Oncology Center and included variables such as hemoglobin levels, type of cancer, presence or absence of metastasis, number of chemotherapy cycles received, location of any metastasis, and the duration since the initial cancer diagnosis. Cancer stage and metastasis status were recorded as separate variables, as Stage IV did not always correspond to confirmed metastatic disease in this setting. Due to the convenience sampling approach, cognitive assessments were conducted regardless of the interval since the last chemotherapy session. To evaluate cognitive function, the Arabic version of the Montreal Cognitive Assessment (MoCA) was utilized [19]. This is a brief, one-page cognitive screening tool that evaluates several domains of cognitive performance including visuospatial and executive function, naming, attention, language, abstraction, memory, and orientation. The total score ranges from 0 to 30, with scores below 26 considered indicative of cognitive impairment. For individuals with twelve or fewer years of formal education, one point is added to their score. The test developers provide the following ranges to grade severity: scores of 18 to 25 may be considered mild cognitive impairment, 10 to 17 moderate cognitive impairment, and less than 10 severe cognitive impairment (mocacognition.com). Psychological status, focusing on symptoms of anxiety and depression, was assessed using the Hospital Anxiety and Depression Scale (HADS), originally developed by Zigmond and Snaith (1983) [20]. The Arabic version of HADS, validated in a Saudi population, demonstrated good reliability with Cronbach’s alpha values of 0.83 for the anxiety subscale and 0.77 for the depression subscale [21]. The scale consists of 14 items, evenly divided between anxiety and depression subscales. Each item is scored from 0 to 3, with higher scores indicating greater symptom severity. Scores for each subscale are classified as normal (0–7), borderline abnormal (8–10), or abnormal (11–21). Quality of life was assessed using the Arabic version of the 12-item Short Form Health Survey (SF-12) [22], a shortened version of the SF-36 that evaluates eight health domains, including physical functioning, role limitations, bodily pain, general health, vitality, social functioning, emotional role, and mental health. The SF-12 generates two composite scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS) [23]. Although the SF-12 primarily measures functional status, these domains were considered indicators of health-related quality of life in this study. Physical and mental health were assessed using the PCS-12 and MCS-12, with reference to the standardized U.S. population norm of 50 (SD = 10). Functional status was interpreted using established SF-12 normative thresholds, with reference to the standardized U.S. population mean of 50 (SD = 10) [24]. For analytical purposes, age was treated as a continuous/ordinal variable in regression analyses to preserve statistical power and avoid loss of information, although it was categorized in Table 1 for descriptive presentation. Scores < 40 (≥ 1 SD below the mean) were considered indicative of reduced health-related quality of life, scores 40–49 as below average, and scores ≥ 50 as average or above. Participants were assigned to categories according to their individual PCS-12 and MCS-12 scores. These scores were calculated using IBM SPSS version 28. Table 1Sociodemographic and clinical profile of the participants (n = 167)CharacteristicsFrequency%Age18–30 years3923.431–50 years7544.9≥ 515331.7Total167100.0SexMale10864.7Female5935.3Total167100.0Marital StatusSingle2213.2Married14083.8Divorced42.4Widowed10.6Total167100.0OccupationEmployed6840.7Unemployed9959.3Total167100.0Educational LevelUneducated6035.9Primary School5532.9High School3219.2Associate’s degree63.6Bachelor’s Degree148.4Master’s Degree00.0Total167100.0Smoking StatusActive Smoker2615.6Ex-smoker4124.6Never smoked10059.9Total167100.0Qat Chewing StatusActive chewer7041.9Past chewer5532.9Never chewed4225.1Total167100.0Hemoglobin Levels< 10 g/dl149.310–12 g/dl5737.712.1–16 g/dl7449.016.1–18 g/dl64.0Missing / Not reported169.6Total167100.0Cancer StageI53.9II1914.8III4938.3IV5543.0Missing / Not reported3939Total167100.0Cancer Metastasis StatusNon-metastatic Cancer11166.5Metastatic Cancer5633.5Total167100.0Type of CancerAnorectal Cancer159.0Breast Cancer84.8Colorectal Cancer3118.6Gastric Cancer1911.4Gastroesophageal Cancer74.2Hodgkin Lymphoma127.2Nasopharyngeal Cancer116.6Oral Tongue Cancer127.2Ovarian Cancer74.2Non-Hodgkin Lymphoma74.2Other3822.8Total167100.0Number of Chemotherapy Cycles< 10 cycles11870.710–20 cycles3621.6> 20 cycles137.8Total167100.0Duration of CancerLess than year11971.3From 1 to 5 years4526.9More than 5 years31.8Total167100.0Site of MetastasisNo Metastasis10965.3Liver2012.0Lung148.4Bone84.8Other169.6Total167100.0 Table 1Sociodemographic and clinical profile of the participants (n = 167)CharacteristicsFrequency%Age18–30 years3923.431–50 years7544.9≥ 515331.7Total167100.0SexMale10864.7Female5935.3Total167100.0Marital StatusSingle2213.2Married14083.8Divorced42.4Widowed10.6Total167100.0OccupationEmployed6840.7Unemployed9959.3Total167100.0Educational LevelUneducated6035.9Primary School5532.9High School3219.2Associate’s degree63.6Bachelor’s Degree148.4Master’s Degree00.0Total167100.0Smoking StatusActive Smoker2615.6Ex-smoker4124.6Never smoked10059.9Total167100.0Qat Chewing StatusActive chewer7041.9Past chewer5532.9Never chewed4225.1Total167100.0Hemoglobin Levels< 10 g/dl149.310–12 g/dl5737.712.1–16 g/dl7449.016.1–18 g/dl64.0Missing / Not reported169.6Total167100.0Cancer StageI53.9II1914.8III4938.3IV5543.0Missing / Not reported3939Total167100.0Cancer Metastasis StatusNon-metastatic Cancer11166.5Metastatic Cancer5633.5Total167100.0Type of CancerAnorectal Cancer159.0Breast Cancer84.8Colorectal Cancer3118.6Gastric Cancer1911.4Gastroesophageal Cancer74.2Hodgkin Lymphoma127.2Nasopharyngeal Cancer116.6Oral Tongue Cancer127.2Ovarian Cancer74.2Non-Hodgkin Lymphoma74.2Other3822.8Total167100.0Number of Chemotherapy Cycles< 10 cycles11870.710–20 cycles3621.6> 20 cycles137.8Total167100.0Duration of CancerLess than year11971.3From 1 to 5 years4526.9More than 5 years31.8Total167100.0Site of MetastasisNo Metastasis10965.3Liver2012.0Lung148.4Bone84.8Other169.6Total167100.0 Sociodemographic and clinical profile of the participants (n = 167) Statistical analysis All collected data were entered and analyzed using the Statistical Package for the Social Sciences (SPSS) version 28 (SPSS Inc., Chicago, IL, USA). Descriptive statistics, including means, standard deviations, frequencies, and percentages, were used to summarize participant characteristics, health status, functional limitations, emotional well-being, and cognitive performance scores. Multiple linear regression analyses were conducted to identify significant factors associated with physical and mental health status (measured by the PCS-12 & MCS-12 score) and cognitive function (measured by the continuous MoCA score). Independent variables included demographic factors, behavioral habits, clinical characteristics, and psychological symptoms. Variable selection for regression analyses was guided by the Biopsychosocial Model and informed by existing psycho-oncology literature. Variables such as age, sex, educational level, smoking status, occupation, comorbidities, cancer stage, and treatment-related factors were chosen a priori based on their established or plausible associations with cognitive and psychological outcomes. This theory-informed approach ensured that our models focused on relevant variables while minimizing the risk of spurious associations. Model assumptions such as multicollinearity, normality, and homoscedasticity were evaluated and met. A significance level of p < 0.05 was applied for all inferential tests. Results Socio-demographic and clinical characteristics A total of 167 adult patients receiving chemotherapy were included in the study. The majority were male (64.7%), married (83.8%), and in advanced cancer stages (III–IV, 81.3%). Participants’ ages ranged from 18 to over 50 years, with 44.9% between 31 and 50 years. Around 40% were employed, and educational attainment varied from no formal education (35.9%) to a bachelor’s degree (8.4%). Lifestyle factors included active smoking (15.6%) and qat chewing (41.9%). Clinically, one-third had metastatic disease, and the most common cancer types were colorectal (18.6%), gastric (11.4%), and anorectal (9.0%). Most patients had undergone fewer than 10 chemotherapy cycles (70.7%) and had been diagnosed within the past year (71.3%). Detailed distributions of all sociodemographic and clinical variables are provided in Table 1. Cognitive function assessment (MoCA Scores) The mean Montreal Cognitive Assessment (MoCA) score among participants was 17.37 (SD = 5.93), with scores ranging from 1 to 28 out of a possible 30. Based on MoCA score interpretation, only 6.0% of patients demonstrated normal cognitive function. Mild cognitive dysfunction was identified in 48.5% of patients, moderate dysfunction in 32.3%, and severe dysfunction in 13.2%. Analysis of MoCA subdomains revealed that the highest mean scores were achieved in orientation (4.68 ± 1.30; 78% of maximum) and attention (3.62 ± 1.68; 60.3% of maximum). The lowest relative scores were observed in language (1.01 ± 0.94; 33.7% of maximum) and visuospatial/executive function (1.89 ± 1.33; 37.8% of maximum). Memory (2.13 ± 1.62; 42.6% of maximum) also showed comparatively low performance (Table 2). Table 2Descriptive statistics for anxiety, depression, and cognitive function assessment scores (N = 167)Variable n %MeanSDPossible RangeActual RangeMoCA Score17.375.930–301–28MoCA Score InterpretationNormal106.0Mild dysfunction8148.5Moderate dysfunction5432.3Severe dysfunction2213.2Memory Score Index8.514.490–150–15MOCA Visuospatial/Executive Function1.891.330–50–5MOCA Naming2.071.010–30–3MOCA Attention3.621.680–60–6MOCA Language1.010.940–30–3MOCA Abstraction1.110.780–20–2MOCA Memory2.131.620–50–5MOCA Orientation4.681.300–60–6Total HADS Anxeity Score6.284.660–210–20HADS Anxiety CategoriesNormal10663.5Borderline abnormal2716.2Abnormal3420.4Total HADS Depression Score7.084.910–210–21HADS Depression CategoryNormal9858.7Borderline abnormal3521.0Abnormal3420.4MOCA Montreal Cognitive Assessment, HADS Hospital Anxiety and Depression Scale Table 2Descriptive statistics for anxiety, depression, and cognitive function assessment scores (N = 167)Variable n %MeanSDPossible RangeActual RangeMoCA Score17.375.930–301–28MoCA Score InterpretationNormal106.0Mild dysfunction8148.5Moderate dysfunction5432.3Severe dysfunction2213.2Memory Score Index8.514.490–150–15MOCA Visuospatial/Executive Function1.891.330–50–5MOCA Naming2.071.010–30–3MOCA Attention3.621.680–60–6MOCA Language1.010.940–30–3MOCA Abstraction1.110.780–20–2MOCA Memory2.131.620–50–5MOCA Orientation4.681.300–60–6Total HADS Anxeity Score6.284.660–210–20HADS Anxiety CategoriesNormal10663.5Borderline abnormal2716.2Abnormal3420.4Total HADS Depression Score7.084.910–210–21HADS Depression CategoryNormal9858.7Borderline abnormal3521.0Abnormal3420.4MOCA Montreal Cognitive Assessment, HADS Hospital Anxiety and Depression Scale Descriptive statistics for anxiety, depression, and cognitive function assessment scores (N = 167) MOCA Montreal Cognitive Assessment, HADS Hospital Anxiety and Depression Scale Anxiety and depression scores (HADS) Assessment of psychological status using the Hospital Anxiety and Depression Scale (HADS) revealed a mean anxiety score of 6.28 (SD = 4.66) and a mean depression score of 7.08 (SD = 4.91). The majority of patients scored within the normal range for anxiety (63.5%) and depression (58.7%). However, borderline abnormal and abnormal anxiety levels were found in 16.2% and 20.4% of patients, respectively. Similarly, 21.0% of patients had borderline abnormal depression scores, and 20.4% were classified as having abnormal depression levels (Table 2). Factors associated with cognitive dysfunction in the participants A multiple linear regression analysis was conducted to examine the determinants of cognitive function, as assessed by the continuous MoCA score. The overall model was statistically significant, F(12, 154) = 10.89, p < 0.001, accounting for 41.7% of the variance in cognitive performance (adjusted R² = 0.417). Increased age (B = − 2.388, p < 0.001) and smoking status (B = − 1.423, p = 0.009) were independently associated with lower MoCA scores, indicative of greater cognitive impairment. Male sex was also significantly correlated with poorer cognitive outcomes (B = − 3.427, p = 0.001). In contrast, higher educational attainment emerged as a robust positive factor associated with cognitive function (B = 2.343, p < 0.001), suggesting that greater levels of education substantially mitigate cognitive impairment. Other variables, including marital status, occupation, qat chewing, cancer metastasis, number of chemotherapy cycles, duration of cancer, symptoms of anxiety and depression, and quality of life, did not exhibit significant associations with cognitive performance in the adjusted model (Table 3). Table 3Multiple linear regression analysis of factors associated with MoCA scores (N = 167)FactorB (Unstandardized)SEβ (Standardized)tp-value95% CI for BToleranceVIFSex–3.3391.033–0.270–3.2340.001–5.379 to − 1.2990.5051.982Age–2.2970.539–0.287–4.259< 0.001–3.363 to − 1.2320.7771.287Marital Status0.9131.0150.0640.9000.370–1.092 to 2.9170.7011.427Occupation0.0600.8920.0050.0670.947–1.702 to 1.8220.6401.562Educational Level 2.448 0.337 0.494 7.254 < 0.001 1.781 to 3.115 0.758 1.320 Smoking Status –1.514 0.555 –0.191 –2.730 0.007 –2.611 to − 0.418 0.716 1.398 Qat Chewing Status0.4080.5220.0550.7820.435–0.623 to 1.4400.7021.424Cancer Metastasis Status–0.5040.828–0.040–0.6080.544–2.141 to 1.1330.8041.244Number of Chemotherapy Cycles0.5400.8200.0570.6580.511–1.080 to 2.1590.4702.127Duration of Cancer0.8591.0600.0720.8110.419–1.235 to 2.9520.4412.266HADS Anxiety Category–0.5500.506–0.075–1.0860.279–1.550 to 0.4500.7351.360HADS Depression Category0.4720.5460.0640.8650.389–0.606 to 1.5490.6421.558PCS-12 Score–0.5090.625–0.053–0.8150.416–1.743 to 0.7250.8171.224MCS-12 Score0.6350.5670.0741.1210.264–0.484 to 1.7550.8141.229Model statistics: R = 0. 682, R² = 0. 466, Adjusted R² = 0. 416, F (14,152) = 9.458, p < 0.001Star sign (*) and bold text indicate significant variable Table 3Multiple linear regression analysis of factors associated with MoCA scores (N = 167)FactorB (Unstandardized)SEβ (Standardized)tp-value95% CI for BToleranceVIFSex–3.3391.033–0.270–3.2340.001–5.379 to − 1.2990.5051.982Age–2.2970.539–0.287–4.259< 0.001–3.363 to − 1.2320.7771.287Marital Status0.9131.0150.0640.9000.370–1.092 to 2.9170.7011.427Occupation0.0600.8920.0050.0670.947–1.702 to 1.8220.6401.562Educational Level 2.448 0.337 0.494 7.254 < 0.001 1.781 to 3.115 0.758 1.320 Smoking Status –1.514 0.555 –0.191 –2.730 0.007 –2.611 to − 0.418 0.716 1.398 Qat Chewing Status0.4080.5220.0550.7820.435–0.623 to 1.4400.7021.424Cancer Metastasis Status–0.5040.828–0.040–0.6080.544–2.141 to 1.1330.8041.244Number of Chemotherapy Cycles0.5400.8200.0570.6580.511–1.080 to 2.1590.4702.127Duration of Cancer0.8591.0600.0720.8110.419–1.235 to 2.9520.4412.266HADS Anxiety Category–0.5500.506–0.075–1.0860.279–1.550 to 0.4500.7351.360HADS Depression Category0.4720.5460.0640.8650.389–0.606 to 1.5490.6421.558PCS-12 Score–0.5090.625–0.053–0.8150.416–1.743 to 0.7250.8171.224MCS-12 Score0.6350.5670.0741.1210.264–0.484 to 1.7550.8141.229Model statistics: R = 0. 682, R² = 0. 466, Adjusted R² = 0. 416, F (14,152) = 9.458, p < 0.001Star sign (*) and bold text indicate significant variable Multiple linear regression analysis of factors associated with MoCA scores (N = 167) Model statistics: R = 0. 682, R² = 0. 466, Adjusted R² = 0. 416, F (14,152) = 9.458, p < 0.001 Star sign (*) and bold text indicate significant variable Health status and quality of life among participants: SF-12 item responses and summary scores Item-level responses Table 4 presents the response frequencies for the individual items of the SF-12, separately for the Physical Component Summary (PCS-12) and the Mental Component Summary (MCS-12). Overall self-rated health was modest, with a mean score of 2.78 ± 1.20; only 5.4% of respondents reported “excellent” health, while the majority reported their health as “fair” (31.7%) or “good” (25.7%). Functional limitations were frequently reported. For example, 31.7% of participants were “limited a lot” and 32.9% “limited a little” in moderate physical activities (mean 2.04 ± 0.82). Similarly, climbing several flights of stairs was difficult for many respondents, with a mean of 2.23 ± 0.78; 44.3% reported being “limited a little.” Table 4Health and functional status responses (N = 167)ItemsResponse frequencies (%)MeanSD123456In general, would you say your health is2.781.192116.231.725.75.4-Limitation in moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf2.040.8231.732.935.3---Limitations in climbing several flights of stairs2.230.7821.634.144.3---Accomplished less than you would like1.370.4863.536.5----Were limited in the kind of work or other activities1.40.4959.940.1----Accomplished less than you would like1.460.5054.545.5----Did not do work or other activities as carefully as usual1.510.5049.150.9----During the past four weeks, how much did pain interfere with your normal work3.051.371523.425.114.422.2-Have you felt calm and peaceful3.041.5622.820.413.820.419.23.6Did you have a lot of energy2.951.6829.316.814.415186.6Have you felt downhearted and blue4.221.8912.6157.87.816.840.1How much of the time has your physical or emotional problems interfered with your social activities3.671.5316.29.612.614.447.3- Table 4Health and functional status responses (N = 167)ItemsResponse frequencies (%)MeanSD123456In general, would you say your health is2.781.192116.231.725.75.4-Limitation in moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf2.040.8231.732.935.3---Limitations in climbing several flights of stairs2.230.7821.634.144.3---Accomplished less than you would like1.370.4863.536.5----Were limited in the kind of work or other activities1.40.4959.940.1----Accomplished less than you would like1.460.5054.545.5----Did not do work or other activities as carefully as usual1.510.5049.150.9----During the past four weeks, how much did pain interfere with your normal work3.051.371523.425.114.422.2-Have you felt calm and peaceful3.041.5622.820.413.820.419.23.6Did you have a lot of energy2.951.6829.316.814.415186.6Have you felt downhearted and blue4.221.8912.6157.87.816.840.1How much of the time has your physical or emotional problems interfered with your social activities3.671.5316.29.612.614.447.3- Health and functional status responses (N = 167) Role limitations were also evident. More than half of the participants indicated that they accomplished less than they would like due to physical health (63.5%) or emotional problems (54.5%), and 59.9% reported being limited in the kind of work they could perform. Nearly half (49.1%) also reported not performing daily activities as carefully as usual. Pain was a notable concern, with a mean score of 3.05 ± 1.37; while 25.1% reported moderate interference of pain with work, 22.2% reported extreme interference. In terms of mental health, 22.8% of respondents reported feeling calm and peaceful “all of the time” or “most of the time,” while nearly one-third indicated rarely or never feeling calm. Energy levels were generally low, with 29.3% reporting they “never” had a lot of energy and only 6.6% reporting “all of the time.” Depressive affect was apparent, as 40.1% reported feeling “downhearted and blue” most or all of the time (mean 4.22 ± 1.89). Finally, social functioning was affected, with a mean score of 3.67 ± 1.53; nearly half of the participants (47.3%) reported that physical or emotional problems interfered with social activities “most of the time.” Summary component scores Physical and mental health, as measured by the SF-12, showed notable variation among participants (Table 5). The mean Physical Component Summary (PCS-12) score was 40.38 ± 7.22 (range: 23.65–62.34), and the mean Mental Component Summary (MCS-12) score was 43.17 ± 8.51 (range: 22.12–61.05), both below the standardized U.S. population norm of 50 (SD = 10), indicating lower physical and mental functioning. Based on established SF-12 normative thresholds (U.S. mean = 50, SD = 10), 35.9% of participants had PCS-12 scores < 40, indicating markedly reduced physical health, while the remaining participants had scores between 40 and 49 or ≥ 50. For mental health, 17.4% had MCS-12 scores < 40, indicating significantly reduced mental health status (Fig. 1). These findings indicate that participants experienced substantial limitations in both physical and mental health, with physical functioning being more impaired than mental well-being. Table 5Average levels of functional status subscales, mental and physical components (N = 167)VariableMeanStd. DeviationMedian95% CI (Lower–Upper)MinimumMaximumPCS1240.387.2240.8439.27–41.4823.6562.34MCS1243.178.5142.3841.87–44.4722.1261.05 Table 5Average levels of functional status subscales, mental and physical components (N = 167)VariableMeanStd. DeviationMedian95% CI (Lower–Upper)MinimumMaximumPCS1240.387.2240.8439.27–41.4823.6562.34MCS1243.178.5142.3841.87–44.4722.1261.05 Average levels of functional status subscales, mental and physical components (N = 167) Fig. 1Distribution of physical and mental health categories based on sample-specific tertiles Distribution of physical and mental health categories based on sample-specific tertiles Factors associated with physical (PCS 12) and mental (MCS 12) health in cancer patients Multiple linear regression analyses were conducted to examine the associations between sociodemographic, lifestyle, and clinical variables and health-related quality of life, measured using the Physical Component Summary (PCS-12) and Mental Component Summary (MCS-12) scores among cancer patients. The independent variables included age, sex, marital status, occupation, educational level, smoking status, qat chewing status, hemoglobin levels, cancer metastasis status, number of chemotherapy cycles, and duration of cancer (Tables 6 and 7). Table 6Linear regression analysis of factors associated with PCS-12 scores (N = 151)FactorBSEβt p 95% CI for BAge0.580.870.060.660.507-1.15, 2.31Sex1.291.670.090.770.442-2.01, 4.58Marital Status-0.381.62-0.02-0.230.816-3.59, 2.83Occupation1.241.460.080.850.399-1.65, 4.12Educational Level 1.49 0.53 0.25 2.84 0.005 0.45, 2.53Smoking Status -2.44 0.87 -0.25 -2.82 0.006 -4.15, -0.73Qat Chewing Status1.260.840.141.500.135-0.40, 2.91Hemoglobin Levels0.760.830.080.910.365-0.89, 2.40Cancer Metastasis Status-0.511.32-0.03-0.380.701-3.12, 2.11Number of Chemotherapy Cycles-1.121.34-0.10-0.840.405-3.76, 1.53Duration of Cancer0.151.710.010.090.930-3.24, 3.54Model summary: R = 0.34, R² = 0.116, Adjusted R² = 0.046, F (11, 139) = 1.65, p = .091, Std. Error = 7.01Star sign (*) and bold text indicate significant variable Table 6Linear regression analysis of factors associated with PCS-12 scores (N = 151)FactorBSEβt p 95% CI for BAge0.580.870.060.660.507-1.15, 2.31Sex1.291.670.090.770.442-2.01, 4.58Marital Status-0.381.62-0.02-0.230.816-3.59, 2.83Occupation1.241.460.080.850.399-1.65, 4.12Educational Level 1.49 0.53 0.25 2.84 0.005 0.45, 2.53Smoking Status -2.44 0.87 -0.25 -2.82 0.006 -4.15, -0.73Qat Chewing Status1.260.840.141.500.135-0.40, 2.91Hemoglobin Levels0.760.830.080.910.365-0.89, 2.40Cancer Metastasis Status-0.511.32-0.03-0.380.701-3.12, 2.11Number of Chemotherapy Cycles-1.121.34-0.10-0.840.405-3.76, 1.53Duration of Cancer0.151.710.010.090.930-3.24, 3.54Model summary: R = 0.34, R² = 0.116, Adjusted R² = 0.046, F (11, 139) = 1.65, p = .091, Std. Error = 7.01Star sign (*) and bold text indicate significant variable Linear regression analysis of factors associated with PCS-12 scores (N = 151) Model summary: R = 0.34, R² = 0.116, Adjusted R² = 0.046, F (11, 139) = 1.65, p = .091, Std. Error = 7.01 Star sign (*) and bold text indicate significant variable Table 7Linear regression analysis of factors associated with MCS12 scores (N = 151)FactorBSEβt p 95% CI for BAge-1.061.06-0.09-1.000.322-3.16, 1.04Sex-1.752.03-0.10-0.860.390-5.75, 2.26Marital Status2.211.970.111.120.264-1.69, 6.11Occupation 3.71 1.77 0.21 2.09 0.038 0.21, 7.22Educational Level0.060.640.010.090.925-1.20, 1.32Smoking Status-0.841.05-0.07-0.800.426-2.92, 1.24Qat Chewing Status-0.371.02-0.04-0.370.714-2.38, 1.63Hemoglobin Levels1.051.010.091.040.299-0.95, 3.05Cancer Metastasis Status 3.41 1.61 0.19 2.12 0.035 0.24, 6.59Number of Chemotherapy Cycles-0.491.62-0.04-0.300.764-3.70, 2.72Duration of Cancer-2.962.08-0.17-1.420.158-7.07, 1.16Model summary: R = 0.32, R² = 0.100, Adjusted R² = 0.028, F (11, 139) = 1.40, p = .181, Std. Error = 8.52Star sign (*) and bold text indicate significant variable Table 7Linear regression analysis of factors associated with MCS12 scores (N = 151)FactorBSEβt p 95% CI for BAge-1.061.06-0.09-1.000.322-3.16, 1.04Sex-1.752.03-0.10-0.860.390-5.75, 2.26Marital Status2.211.970.111.120.264-1.69, 6.11Occupation 3.71 1.77 0.21 2.09 0.038 0.21, 7.22Educational Level0.060.640.010.090.925-1.20, 1.32Smoking Status-0.841.05-0.07-0.800.426-2.92, 1.24Qat Chewing Status-0.371.02-0.04-0.370.714-2.38, 1.63Hemoglobin Levels1.051.010.091.040.299-0.95, 3.05Cancer Metastasis Status 3.41 1.61 0.19 2.12 0.035 0.24, 6.59Number of Chemotherapy Cycles-0.491.62-0.04-0.300.764-3.70, 2.72Duration of Cancer-2.962.08-0.17-1.420.158-7.07, 1.16Model summary: R = 0.32, R² = 0.100, Adjusted R² = 0.028, F (11, 139) = 1.40, p = .181, Std. Error = 8.52Star sign (*) and bold text indicate significant variable Linear regression analysis of factors associated with MCS12 scores (N = 151) Model summary: R = 0.32, R² = 0.100, Adjusted R² = 0.028, F (11, 139) = 1.40, p = .181, Std. Error = 8.52 Star sign (*) and bold text indicate significant variable Physical health (PCS-12) In the PCS-12 model, the dependent variable was the Physical Component Summary (PCS-12) score, and the independent variables included age, sex, marital status, occupation, educational level, smoking status, qat chewing status, hemoglobin levels, cancer metastasis status, number of chemotherapy cycles, and duration of cancer. The model explained 11.6% of the variance in physical health scores (R² = 0.116, adjusted R² = 0.046), with a standard error of estimate of 7.01. The overall regression was not statistically significant (F(11, 139) = 1.651, p = 0.091), indicating that the included variables collectively accounted for only a limited proportion of variation in PCS-12 scores. Although some coefficients reached statistical significance, these should be interpreted with caution and not as confirmed independent predictors in the absence of overall model significance. Rather, these findings are considered exploratory and hypothesis-generating. Within this context, educational level and smoking status showed statistically significant coefficients. Higher educational level was associated with higher PCS-12 scores (B = 1.492, SE = 0.526, β = 0.245, t = 2.838, p = 0.005, 95% CI [0.452, 2.531]), which may indicate a potential relationship with better physical health. In contrast, smoking status was negatively associated with PCS-12 scores (B = − 2.438, SE = 0.865, β = −0.253, t = − 2.818, p = 0.006, 95% CI [− 4.148, − 0.727]), which may reflect poorer physical health-related quality of life among smokers. However, these associations should be interpreted cautiously given the non-significant overall model. All other variables, including age, sex, marital status, occupation, qat chewing status, hemoglobin levels, cancer metastasis status, number of chemotherapy cycles, and duration of cancer, were not significantly associated with PCS-12 scores (all p > 0.05). Mental health (MCS-12) In the MCS-12 model, the dependent variable was the Mental Component Summary (MCS-12) score, and the independent variables were the same as those included in the PCS-12 model: age, sex, marital status, occupation, educational level, smoking status, qat chewing status, hemoglobin levels, cancer metastasis status, number of chemotherapy cycles, and duration of cancer. The model explained 10.0% of the variance in mental health scores (R² = 0.100, adjusted R² = 0.028), with a standard error of estimate of 8.52. Similar to the PCS-12 model, the overall regression was not statistically significant (F(11, 139) = 1.397, p = 0.181), indicating that the included variables collectively accounted for only a limited proportion of variation in mental health outcomes. Although some variables yielded statistically significant coefficients, these should be interpreted cautiously and not as confirmed predictors in the absence of overall model significance. Rather, they should be considered exploratory and hypothesis-generating. Within this context, occupation was positively associated with MCS-12 scores (B = 3.712, SE = 1.772, β = 0.210, t = 2.094, p = 0.038, 95% CI [0.208, 7.217]), suggesting better mental health-related quality of life among employed patients or those engaged in work. Cancer metastasis status was also positively associated with MCS-12 scores (B = 3.412, SE = 1.606, β = 0.191, t = 2.124, p = 0.035, 95% CI [0.236, 6.588]). However, this finding was unexpected and should be interpreted with particular caution. Given the non-significant overall model and the number of predictors examined, this association may reflect a chance finding (Type I error) rather than a true effect. While explanations such as adaptation or response shift have been proposed in previous literature, these cannot be confirmed within the present study and should not be overinterpreted. Accordingly, this result is best viewed as exploratory and hypothesis-generating. All other variables, including age, sex, marital status, educational level, smoking status, qat chewing status, hemoglobin levels, number of chemotherapy cycles, and duration of cancer, were not significantly associated with MCS-12 scores (all p > 0.05). Overall, although the PCS-12 and MCS-12 models explained a modest proportion of variance and were not statistically significant, some variables showed potential individual-level associations. These findings should be interpreted cautiously, particularly given the cross-sectional design, and are intended to inform future research rather than provide confirmatory evidence. Discussion Cognitive dysfunction, often referred to as cancer-related cognitive impairment, is increasingly recognized as a significant side effect that negatively impacts patients’ quality of life and treatment adherence [8, 9, 12]. Despite its importance, research on this topic remains scarce in the Arab region. To date, studies have been reported only from Saudi Arabia [25], Egypt [26], and Lebanon [27], primarily addressing breast cancer patients or mixed populations undergoing chemotherapy. In Yemen, however, this aspect of cancer care has not been previously investigated. The present study constitutes the first effort in the country to examine screen-detected cognitive dysfunction among patients receiving chemotherapy, aiming not only to document its prevalence at the screening level but also to identify key factors—such as sociodemographic, clinical, and psychological factors—that may be associated with its occurrence. Among 167 cancer patients, cognitive impairment was highly prevalent, affecting 94% of participants, with moderate-to-severe impairment observed in approximately 45.5%. Given the high proportion of participants with no formal education, the observed 94% rate reflects screen-positive cognitive vulnerability rather than confirmed cognitive impairment, and should be interpreted in this context. These results align with previous studies reporting significant rates of cognitive dysfunction among patients receiving chemotherapy [28–30]. About 20% of patients had borderline or abnormal anxiety and depression. Mean PCS-12 and MCS-12 scores were 40.4 and 43.2, indicating reduced quality of life. Regression analyses indicated that poorer cognition was associated with older age, male sex, and smoking, while higher education was protective. Additionally, higher education showed a positive association with physical health, smoking showed a negative association, employment was associated with better mental health, and metastasis was unexpectedly associated with higher mental health scores. Beyond chemotherapy exposure, cognitive performance as measured by the MoCA may be influenced by contextual and patient-related factors, including educational level (with the standard one-point education adjustment applied), nutritional status, anemia, fatigue, psychological distress, and stress associated with living in a conflict-affected environment. These factors may affect screening performance and could contribute to the elevated proportion identified in this population. Therefore, the findings should be understood within this broader socio-clinical context. Within the current sample, visuospatial/executive functions and language abilities emerged as the most affected domains, whereas orientation and attention showed relatively higher mean scores. Nonetheless, even the attention score (3.62/6) reflected a notable decline. This pattern may seem at odds with earlier studies, which often report attention as one of the most impaired domains [25, 31, 32]. However, the predominance of illiteracy among participants provides important context: literacy and educational experience are known to shape performance in attention, language, and visuospatial tasks. Thus, the relatively preserved orientation and attention scores may reflect basic cognitive capacities that are less education-dependent, whereas deficits in language and visuospatial/executive domains could be exacerbated by limited educational exposure. Importantly, these results underscore the role of baseline cognitive reserve—which is shaped by lifestyle, norms, and cultural context [33]—in influencing how chemotherapy-related impairment manifests in different populations. Education may be linked both to true cognitive reserve and to test performance itself, which may further influence MoCA scores in this population. Although a one-point correction was applied for participants with low educational attainment, residual effects of education and literacy may still have influenced MoCA performance and contributed to lower scores. The study further identified four significant factors associated with cognitive decline: age, smoking status, gender, and educational level. Older patients and patients with lower educational levels experienced more significant declines in their cognitive abilities which is consistent with the findings of other studies [34–36]. Proposed justifications for the significance of those two factors included the fact that older people already experience cognitive abilities reduction with aging that is exacerbated by chemotherapy and that people with lower education levels don’t usually carry out tasks that require high cognitive functioning. Similarly, the deleterious effects of smoking on chemotherapy receiving patients were also noticed in other studies [37] although the specific effect on cognitive functions is a matter of controversy and requires further research. Regarding gender, male showed higher rates if cognitive decline. This finding is in line with those of Eberhardt et al. who found that males performed worse than females in specific cognitive fields [38]. However, the findings of some other studies conflict the finding of this study as thew showed higher cognitive decline in females [31, 35]. This is contradiction might be an indicator that the effect of the gender is determined by other factors rather than the gender being the factor of influence itself. The poorer cognitive performance observed among men and smokers in our sample may reflect both biological and sociocultural influences. Biologically, chronic tobacco exposure can trigger neuroinflammation, oxidative stress, and cerebrovascular changes that impair attention, memory, and executive function [39, 40]. Smoking may also worsen cancer-related fatigue and hypoxia, contributing further to cognitive decline [41]. Additionally, sex-related neurocognitive differences may play a role, as women often show greater resilience in verbal memory and some executive functions, potentially due to hormonal or neural network variations [42]. Interestingly, no significant association was found between depression or anxiety and cognitive dysfunction in this study. This aligns with [43] and [44], who similarly reported weak or absent links between mood symptoms and cognition [43]. On the other hand, other studies—both in the MENA region [25, 27, 45] and globally —have demonstrated that depression and anxiety can exacerbate cognitive impairment, particularly when combined with fatigue [46, 47]. These discrepancies highlight the need for future research to examine how psychological distress interacts with fatigue and other contextual variables in shaping cognitive outcomes. Qat use represents an important contextual factor in this population, as 41.9% of participants reported current chewing. Qat contains cathinone, a stimulant with known psychoactive and potential neurocognitive effects, including impacts on attention, mood, and executive function [48]. In the present study, qat use was modeled as a binary variable and was not significantly associated with outcomes; however, this approach may not adequately capture dose-dependent or chronic effects. The absence of detailed information on frequency, duration, and intensity of use limits interpretation. Future studies should incorporate more granular measures of qat consumption to better understand its potential role in cognitive and psychological outcomes among cancer patients. Similarly, marital status and quality of life were not significantly associated with cognitive dysfunction in this study. This finding diverges from evidence in Lebanon, where being unmarried and having lower quality of life were associated with greater cognitive impairment [27], and from studies linking QoL more broadly with cognitive outcomes [49, 50]. These differences may be explained by cultural and social contexts, where strong family and community support networks could buffer the effects of marital status and perceived QoL on cognitive health. Methodological variations, such as assessment tools and population characteristics, may also account for the inconsistency, underscoring the importance of exploring these factors in future multi-country studies. Beyond cognitive outcomes, the present study also assessed broader health-related quality of life (HRQoL). Participants experienced significant limitations in both physical and mental health, with mean PCS-12 and MCS-12 scores below the U.S. norm. When categorized into tertiles based on the distribution of scores within the sample, 35.9% were classified as having low physical health and 17.4% as having low mental health, with physical functioning more impaired. These findings align with research from Jordan, which similarly reported reduced physical functioning among women with breast cancer [24], and from Ethiopia, where poor HRQoL was linked to impaired physical functioning, unmet needs, and low satisfaction with care [51]. Together, these findings highlight physical functioning as a critical driver of HRQoL, though variations in mental health outcomes likely reflect cultural, clinical, and systemic differences across settings. Regression analyses in the current study identified educational level and smoking status as factors associated with PCS-12, while occupation and cancer metastasis were associated with MCS-12. However, given that both models were not statistically significant overall, these associations should not be interpreted as definitive predictors but rather as exploratory findings that may guide future research. Other variables, including age, sex, marital status, and number of chemotherapy cycles, were not significant in either model. These findings illustrate that both sociodemographic and clinical variables contribute to HRQoL, though their explanatory power was modest (11.6% of PCS-12 and 10% of MCS-12 variance). Adding a wider perspective, a large Indian study involving over 12,000 patients demonstrated that older age, low education, chemotherapy, palliative care, surgery, advanced stage, and progressive disease all contributed to poorer HRQoL [52]. This reinforces the dual importance of sociodemographic and clinical severity factors across diverse populations. Similarly, the Ethiopian study at Dessie Comprehensive Specialized Hospital identified unmet needs and low satisfaction with care as key contributors to poor HRQoL [53], findings that resonate with the present results where metastasis status and health behaviours such as smoking were influential. Comparisons with Saudi Arabia reveal partial alignment. Ahmed et al. (2018) identified age, marital status, and employment as significant factors associated with HRQoL [54], whereas these factors were not significant in the current study. Still, both studies underscore the role of education and occupation in shaping outcomes, even if the precise factors differ. Collectively, the regional and international evidence underscores that while education, occupation, and disease status consistently shape HRQoL, the influence of variables such as age, marital status, and psychological distress may be context specific. Overall, these comparisons underscore that factors associated with HRQoL may vary across populations due to cultural, social, and healthcare system differences. While factors like education, occupation, and disease status consistently influence quality of life, others, such as age and marital status, may be context-specific. This highlights the multifactorial nature of HRQoL and the need to consider both clinical and socio-environmental determinants when designing interventions to improve outcomes for cancer patients. These findings have important implications for clinical practice, institutional policy, and patient care in Yemen and similar resource-limited settings. Clinically, routine cognitive and psychological screening should be implemented for high-risk patients. Hospitals should integrate supportive care programs into standard chemotherapy protocols, with trained staff using validated tools like MoCA and HADS. Patient care interventions should include cognitive training, psychosocial support, smoking cessation, and physical rehabilitation. Future research should focus on longitudinal assessments and multi-center collaborations to provide broader insights. This study has several limitations. Its cross-sectional design prevents causal conclusions regarding the relationship between chemotherapy exposure and cognitive or psychological outcomes. As the study was conducted at a single oncology center, the findings may not be fully generalizable to all Yemeni cancer patients. The use of convenience sampling may limit representativeness and introduce selection bias. Although recruitment and data collection were conducted by four trained clinical pharmacists using standardized procedures, formal inter-rater reliability was not assessed, which may introduce variability in interviewer-administered measures. Self-reported measures may be influenced by recall bias, literacy, or cultural factors. Additionally, because data were collected through interviewer-administered assessments, there is a possibility of social desirability bias, whereby participants may have been reluctant to disclose sensitive cognitive or psychological symptoms. This may have led to underreporting and a potential underestimation of the prevalence of adverse outcomes such as anxiety, depression, and cognitive impairment. Detailed information on nutritional status, socioeconomic conditions, fatigue, and specific treatment regimens—including the interval since the last chemotherapy session, severity of anemia, chemotherapy regimen type, and concomitant medications—particularly central nervous system (CNS)-active medications such as opioids, benzodiazepines, and corticosteroids—was not fully captured. In addition, qat use was assessed as a binary variable (yes/no) without accounting for frequency, duration, or intensity of use, which may have limited the ability to detect its potential dose-dependent neurocognitive effects. While standardized instruments (MoCA, HADS, SF-12) were used, the lack of Yemeni-specific norms may affect interpretation, and training for scale administration, although provided, was not externally certified. The relatively small sample size limits power for detecting subtle effects or interactions, and multiple variables were analyzed relative to the sample size, which may increase the risk of overfitting. There was no comparison group of non-chemotherapy patients or pre-chemotherapy baseline, which limits the ability to attribute findings specifically to chemotherapy exposure. Finally, potential interviewer bias, site-specific effects, and unmeasured confounders cannot be entirely ruled out. Despite these limitations, this study provides valuable baseline data on cognitive dysfunction, psychological distress, and HRQoL among chemotherapy patients in a resource-limited setting, supporting targeted interventions, policy development, and future longitudinal and multi-center research. Conclusion This study highlights the substantial burden of cognitive, psychological, and quality-of-life impairments among Yemeni cancer patients receiving chemotherapy, reflecting challenges faced in other resource-limited settings. Nearly all participants exhibited some degree of screen-detected cognitive dysfunction, with deficits most pronounced in the language and visuospatial/executive domains. Anxiety, depression, and lower physical and mental functioning scores were also prevalent. Demographic and lifestyle factors—such as age, sex, education, smoking, and employment—showed associations with outcomes; however, findings related to quality-of-life models should be interpreted as exploratory due to the lack of overall model significance. These findings emphasize the need for integrated supportive care programs that address not only the physical but also the cognitive and psychological well-being of patients. The findings further support the importance of routine cognitive screening in oncology settings. Furthermore, longitudinal and interventional studies are recommended to better understand causality and to develop effective strategies to mitigate cognitive and psychological impairments. Tailored interventions, including patient education, psychosocial support, and strategies to enhance cognitive resilience, are essential to improve daily functioning, treatment adherence, and overall quality of life in cancer populations within resource-limited contexts like Yemen.